A citation-based method for searching scientific literature

Yasmin Jauhari, Melissa Ruth Gannon, David Dodwell, Kieran Horgan, Carmen Tsang, Karen Clements, Jibby Medina, Sarah Tang, Ruth Pettengell, David Alan Cromwell. Eur J Surg Oncol 2020
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort.
Sophie Frank, Matthieu Carton, Coraline Dubot, Mario Campone, Barbara Pistilli, Florence Dalenc, Audrey Mailliez, Christelle Levy, Véronique D'Hondt, Marc Debled,[...]. Breast 2020
2
50

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study.
Ahmad Awada, Agustin A Garcia, Stephen Chan, Guy H M Jerusalem, Robert E Coleman, Manon T Huizing, Aminder Mehdi, Sue M O'Reilly, John T Hamm, Peter J Barrett-Lee,[...]. Lancet Oncol 2013
44
50


The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial.
S-E Al-Batran, J Bischoff, G von Minckwitz, A Atmaca, U Kleeberg, I Meuthen, G Morack, W Lerbs, D Hecker, J Sehouli,[...]. Br J Cancer 2006
45
50

Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients.
J L Blum, V Dieras, P M Lo Russo, J Horton, O Rutman, A Buzdar, B Osterwalder. Cancer 2001
313
50

Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
Antonio González-Martín, Emilio Alba, Eva Ciruelos, Javier Cortés, Antonio Llombart, Ana Lluch, Raquel Andrés, Isabel Álvarez, José Manuel Aramendía, Francisco Ayala de la Peña,[...]. Curr Cancer Drug Targets 2016
7
50

Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Anna Lee, Se-Il Go, Won Sup Lee, Un Seok Lee, Moon Jin Kim, Myoung Hee Kang, Gyeong-Won Lee, Hoon-Gu Kim, Jung Hun Kang, Kyung-Nyeo Jeon,[...]. Tumori 2015
3
50

Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane.
Sunil Verma, Nan Soon Wong, Maureen Trudeau, Anil Joy, John Mackey, George Dranitsaris, Mark Clemons. Am J Clin Oncol 2007
15
50

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S Olivo, James Song, Corina E Dutcus, Peter A Kaufman. Breast Cancer (Auckl) 2016
31
50


Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
M Campone, H Cortes-Funes, D Vorobiof, M Martin, C F Slabber, E Ciruelos, E Bourbouloux, C Mendiola, F M Delgado, C Colin,[...]. Br J Cancer 2006
45
50

Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Alessandra Fabi, Diana Giannarelli, Paola Malaguti, Gianluigi Ferretti, Sabrina Vari, Paola Papaldo, Cecilia Nisticò, Mauro Caterino, Roy De Vita, Marcella Mottolese,[...]. Drug Des Devel Ther 2015
14
50

NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
William J Gradishar, Benjamin O Anderson, Ron Balassanian, Sarah L Blair, Harold J Burstein, Amy Cyr, Anthony D Elias, William B Farrar, Andres Forero, Sharon Hermes Giordano,[...]. J Natl Compr Canc Netw 2017
212
50

Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-/taxane-based chemotherapy.
Pierre Fumoleau, Hernan Cortés-Funes, Amina B Taleb, Stephen Chan, Mario Campone, Jean-Christophe Pouget, Michèle Tubiana-Hulin, Conrad F Slabber, Isabelle Caroff-Paraïso, Albert S Alberts,[...]. Am J Clin Oncol 2009
23
50


Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
S E Jones, J Erban, B Overmoyer, G T Budd, L Hutchins, E Lower, L Laufman, S Sundaram, W J Urba, K I Pritchard,[...]. J Clin Oncol 2005
353
50

A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Carlo Palmieri, Constantine Alifrangis, David Shipway, Tri Tat, Vivienne Watson, Diane Mackie, Marie Emson, R Charles Coombes. Oncologist 2012
3
50

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.
F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, N Harbeck, B Aguilar Lopez, C H Barrios, J Bergh,[...]. Ann Oncol 2018
505
50

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Javier Cortes, Joyce O'Shaughnessy, David Loesch, Joanne L Blum, Linda T Vahdat, Katarina Petrakova, Philippe Chollet, Alexey Manikas, Veronique Diéras, Thierry Delozier,[...]. Lancet 2011
641
50

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.
Erika Hamilton, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, Kimberly Blackwell. Clin Breast Cancer 2013
35
50

Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Ann H Partridge, R Bryan Rumble, Lisa A Carey, Steven E Come, Nancy E Davidson, Angelo Di Leo, Julie Gralow, Gabriel N Hortobagyi, Beverly Moy, Douglas Yee,[...]. J Clin Oncol 2014
153
50

Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
Linda J M Oostendorp, Peep F M Stalmeier, A Rogier T Donders, Winette T A van der Graaf, Petronella B Ottevanger. Lancet Oncol 2011
45
50

Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States.
Angela B Mariotto, Ruth Etzioni, Marc Hurlbert, Lynne Penberthy, Musa Mayer. Cancer Epidemiol Biomarkers Prev 2017
184
50

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
F Cardoso, A Costa, L Norton, E Senkus, M Aapro, F André, C H Barrios, J Bergh, L Biganzoli, K L Blackwell,[...]. Ann Oncol 2014
256
50

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer.
Amy E Chang, Qian V Wu, Isaac C Jenkins, Jennifer M Specht, Vijayakrishna K Gadi, Julie R Gralow, Lupe G Salazar, Brenda F Kurland, Hannah M Linden. Clin Breast Cancer 2018
8
50

Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials.
Fausto Petrelli, Sandro Barni, Giacomo Bregni, Filippo de Braud, Serena Di Cosimo. Breast Cancer Res Treat 2016
15
50

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.
Kathy D Miller, Linnea I Chap, Frankie A Holmes, Melody A Cobleigh, P Kelly Marcom, Louis Fehrenbacher, Maura Dickler, Beth A Overmoyer, James D Reimann, Amy P Sing,[...]. J Clin Oncol 2005
995
50

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.
Edith A Perez, Guillermo Lerzo, Xavier Pivot, Eva Thomas, Linda Vahdat, Linda Bosserman, Patrice Viens, Can Cai, Brian Mullaney, Ronald Peck,[...]. J Clin Oncol 2007
299
50

Paclitaxel in Breast Cancer.
Perez. Oncologist 1998
66
50

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Christopher Lobo, Gilberto Lopes, Odalys Baez, Aurelio Castrellon, Annapoorna Ferrell, Connie Higgins, Erin Hurley, Judith Hurley, Isildinha Reis, Stephen Richman,[...]. Breast Cancer Res Treat 2010
56
50

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
50

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both.
Edith A Perez, David W Hillman, James A Mailliard, James N Ingle, J Michael Ryan, Tom R Fitch, Kendrith M Rowland, Carl G Kardinal, James E Krook, John W Kugler,[...]. J Clin Oncol 2004
91
50

Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.
D C Talbot, V Moiseyenko, S Van Belle, S M O'Reilly, E Alba Conejo, S Ackland, P Eisenberg, D Melnychuk, T Pienkowski, H-U Burger,[...]. Br J Cancer 2002
154
50

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes.
Joanne L Blum, Michael A Savin, Gerald Edelman, John E Pippen, Nicholas J Robert, Brian V Geister, Robert L Kirby, Alicia Clawson, Joyce A O'Shaughnessy. Clin Breast Cancer 2007
116
50

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
Linda T Vahdat, Brian Pruitt, Carol J Fabian, Ragene R Rivera, David A Smith, Elizabeth Tan-Chiu, Jonathan Wright, Antoinette R Tan, Noshir A Dacosta, Ellen Chuang,[...]. J Clin Oncol 2009
176
50


Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Shigeto Maeda, Michiyo Saimura, Shigeki Minami, Kaname Kurashita, Reiki Nishimura, Yuichiro Kai, Hiroshi Yano, Kohjiro Mashino, Shoshu Mitsuyama, Mototsugu Shimokawa,[...]. Breast 2017
21
50



Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology.
Benoit Beuselinck, Hans Wildiers, Wim Wynendaele, Luc Dirix, Jean-Pierre Kains, Robert Paridaens. Crit Rev Oncol Hematol 2010
16
50

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
P Fumoleau, R Largillier, C Clippe, V Dièras, H Orfeuvre, T Lesimple, S Culine, B Audhuy, D Serin, H Curé,[...]. Eur J Cancer 2004
212
50

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Raffaella Palumbo, Federico Sottotetti, Giuseppe Trifirò, Elena Piazza, Antonella Ferzi, Anna Gambaro, Elena Giulia Spinapolice, Emma Pozzi, Barbara Tagliaferri, Cristina Teragni,[...]. Drug Des Devel Ther 2015
27
50

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Philippe Aftimos, Laura Polastro, Lieveke Ameye, Christiane Jungels, Jalal Vakili, Marianne Paesmans, Joanne van den Eerenbeemt, Alfino Buttice, Andrea Gombos, Dominique de Valeriola,[...]. Eur J Cancer 2016
21
50

The treatment of early breast cancer in women over the age of 70.
A Ring, M Reed, R Leonard, I Kunkler, H Muss, H Wildiers, L Fallowfield, A Jones, R Coleman. Br J Cancer 2011
41
50

Eribulin in Male Patients With Breast Cancer: The First Report of Clinical Outcomes.
Francesco Giotta, Luigi Acito, Giampiero Candeloro, Pietro Del Medico, Gennaro Gadaleta-Caldarola, Guido Giordano, Rossana Gueli, Antonio Lugini, Valentina Magri, Marta Mandarà,[...]. Oncologist 2016
5
50

Coming of age: breast cancer in seniors.
Hyman B Muss. Oncologist 2011
16
50

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).
Shoichiro Ohtani, Takahiro Nakayama, Tetsuhiro Yoshinami, Ken-Ichi Watanabe, Fumikata Hara, Yasuaki Sagara, Hidetoshi Kawaguchi, Kenji Higaki, Nobuki Matsunami, Yoshie Hasegawa,[...]. Breast Cancer 2018
8
50

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply.
Peter Schmid, Stephen Y Chui, Leisha A Emens. N Engl J Med 2019
21
50

The role of pharmacogenetics in capecitabine efficacy and toxicity.
S W Lam, H J Guchelaar, E Boven. Cancer Treat Rev 2016
31
50

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
Joanne L Blum, Joseph Kohles, Edward McKenna, Nana Scotto, Sylvia Hu, Dawn Odom, James A Kaye, Stefan Glück. Breast Cancer Res Treat 2011
11
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.